Research programme: cannabinoid-based therapeutics - CannaKids/CURE Pharmaceutical

Drug Profile

Research programme: cannabinoid-based therapeutics - CannaKids/CURE Pharmaceutical

Latest Information Update: 02 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CannaKids; Cure Pharmaceutical
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 18 May 2017 CURE Pharmaceuticals has a patent published by the USPTO entitled "Pharmaceutical Composition with Ionically Crosslinked Polymer Encapsulation of Active Ingredient" which covers CureFilm™ drug delivery technology
  • 06 Mar 2017 CURE Pharmaceutical and CannKids enter research collaboration to develop cannabinoid-based therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top